Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Significant Drop in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 6,100 shares, a decrease of 44.5% from the May 31st total of 11,000 shares. Based on an average daily volume of 30,200 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.

Cocrystal Pharma Stock Performance

Shares of COCP traded down $0.22 during mid-day trading on Friday, reaching $2.33. The company had a trading volume of 18,690 shares, compared to its average volume of 21,477. Cocrystal Pharma has a 52 week low of $1.33 and a 52 week high of $3.29. The company has a market capitalization of $23.71 million, a price-to-earnings ratio of -1.34 and a beta of 1.39. The firm has a 50-day moving average price of $2.10 and a 200 day moving average price of $1.76.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.15. As a group, research analysts forecast that Cocrystal Pharma will post -2.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Cocrystal Pharma in a research note on Tuesday, May 14th.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.